These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 11786565)

  • 21. The role of FDG-PET in the selection of patients with colorectal liver metastases.
    Wiering B; Krabbe PF; Dekker HM; Oyen WJ; Ruers TJ
    Ann Surg Oncol; 2007 Feb; 14(2):771-9. PubMed ID: 17086488
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET).
    Fernandez FG; Drebin JA; Linehan DC; Dehdashti F; Siegel BA; Strasberg SM
    Ann Surg; 2004 Sep; 240(3):438-47; discussion 447-50. PubMed ID: 15319715
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Controversies in the management of colorectal liver metastases: role of PET and PET/CT.
    Wiering B; Vogel WV; Ruers TJ; Oyen WJ
    Dig Surg; 2008; 25(6):413-20. PubMed ID: 19212113
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Respiratory gated and prolonged acquisition 18F-FDG PET improve preoperative assessment of colorectal liver metastases.
    Revheim ME; Haugvik SP; Johnsrud K; Mathisen Ø; Fjeld JG; Skretting A
    Acta Radiol; 2015 Apr; 56(4):397-403. PubMed ID: 24682406
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of patients with liver metastases from colorectal cancer for locally ablative treatment with laser induced thermotherapy. Impact of PET with 18F-fluorodeoxyglucose on therapeutic decisions.
    Amthauer H; Denecke T; Hildebrandt B; Rühl R; Miersch A; Nicolaou A; Ruf J; Plotkin M; Hänninen EL; Stroszczynski C; Gutberlet M; Langrehr J; Riess H; Ricke J
    Nuklearmedizin; 2006; 45(4):177-84. PubMed ID: 16964344
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Improved selection of patients for hepatic surgery of colorectal liver metastases with (18)F-FDG PET: a randomized study.
    Ruers TJ; Wiering B; van der Sijp JR; Roumen RM; de Jong KP; Comans EF; Pruim J; Dekker HM; Krabbe PF; Oyen WJ
    J Nucl Med; 2009 Jul; 50(7):1036-41. PubMed ID: 19525451
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical impact of FDG PET-CT in patients with potentially operable metastatic colorectal cancer.
    Briggs RH; Chowdhury FU; Lodge JP; Scarsbrook AF
    Clin Radiol; 2011 Dec; 66(12):1167-74. PubMed ID: 21867996
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Unique site- and time-specific patterns of recurrence following resection of colorectal carcinoma hepatic metastases in patients staged by FDG-PET.
    Finkelstein SE; Fernandez FG; Dehdashti F; Siegel BA; Hawkins WG; Linehan DC; Strasberg SM
    J Hepatobiliary Pancreat Surg; 2008; 15(5):483-7. PubMed ID: 18836801
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of FDG-PET in surgical management of patients with colorectal liver metastases.
    Teague BD; Morrison CP; Court FG; Chin VT; Costello SP; Kirkwood ID; Maddern GJ
    ANZ J Surg; 2004 Aug; 74(8):646-52. PubMed ID: 15315564
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical value of whole-body emission tomography in potentially curable colorectal liver metastases.
    Topal B; Flamen P; Aerts R; D'Hoore A; Filez L; Van Cutsem E; Mortelmans L; Penninckx F
    Eur J Surg Oncol; 2001 Mar; 27(2):175-9. PubMed ID: 11345944
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Routine (18)F-FDG PET preoperative staging of colorectal cancer: comparison with conventional staging and its impact on treatment decision making.
    Kantorová I; Lipská L; Bêlohlávek O; Visokai V; Trubaĉ M; Schneiderová M
    J Nucl Med; 2003 Nov; 44(11):1784-8. PubMed ID: 14602860
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of ¹⁸F-FDG-PET in decision making for liver metastectomy of colorectal cancer.
    McLeish AR; Lee ST; Byrne AJ; Scott AM
    ANZ J Surg; 2012; 82(1-2):30-5. PubMed ID: 22507492
    [TBL] [Abstract][Full Text] [Related]  

  • 33. FDG-PET improves management of patients with colorectal liver metastases allocated for local treatment: a consecutive prospective study.
    Sørensen M; Mortensen FV; Høyer M; Vilstrup H; Keiding S;
    Scand J Surg; 2007; 96(3):209-13. PubMed ID: 17966746
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preoperative staging of patients with liver metastases of colorectal carcinoma. Does PET/CT really add something to multidetector CT?
    Ramos E; Valls C; Martinez L; Lladó L; Torras J; Ruiz S; Gamez C; Serrano T; Fabregat J; Rafecas A
    Ann Surg Oncol; 2011 Sep; 18(9):2654-61. PubMed ID: 21431987
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of FDG-PET staging in selecting the optimum patient for hepatic resection of metastatic colorectal cancer.
    Strasberg SM; Dehdashti F
    J Surg Oncol; 2010 Dec; 102(8):955-9. PubMed ID: 21165998
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: correlation with histopathologic and CT findings.
    Abdel-Nabi H; Doerr RJ; Lamonica DM; Cronin VR; Galantowicz PJ; Carbone GM; Spaulding MB
    Radiology; 1998 Mar; 206(3):755-60. PubMed ID: 9494497
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Staging recurrent metastatic colorectal carcinoma with PET.
    Delbeke D; Vitola JV; Sandler MP; Arildsen RC; Powers TA; Wright JK; Chapman WC; Pinson CW
    J Nucl Med; 1997 Aug; 38(8):1196-201. PubMed ID: 9255148
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of (18)F-FDG PET/CT in initial staging of patients with locally advanced breast carcinoma with an emphasis on M staging.
    Mittal BR; Manohar K; Kashyap R; Bhattacharya A; Singh B; Singh G
    Hell J Nucl Med; 2011; 14(2):135-9. PubMed ID: 21761015
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Value of 18F-fluoro-2-deoxyglucose positron emission tomography in the evaluation of recurrent colorectal cancer.
    Hung GU; Shiau YC; Tsai SC; Chao TH; Ho YJ; Kao CH
    Anticancer Res; 2001; 21(2B):1375-8. PubMed ID: 11396217
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluating 90Y-glass microsphere treatment response of unresectable colorectal liver metastases by [18F]FDG PET: a comparison with CT or MRI.
    Wong CY; Salem R; Raman S; Gates VL; Dworkin HJ
    Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):815-20. PubMed ID: 12029557
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.